

Res Chem Intermed (2015) 41:1789–1801
DOI 10.1007/s11164-013-1312-z

Synthesis of new pyrimidine derivatives and their antiproliferative activity against selected human cancer cell lines

S. M. Awad · O. A. Fathalla · J. Wietrzyk ·
M. Milczarek · A. M. Soliman · Mosaad S. Mohamed

Received: 14 February 2013 / Accepted: 11 June 2013 / Published online: 27 June 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract 6-Amino-2-thiouracil (**1**) was condensed with benzenesulfonyl chloride and *p*-toluenesulfonyl chloride in presence of pyridine as an acid binder to give sulfonamides **2a**, **b**, which could be methylated in basic medium to give methylmercapto derivatives **3a**, **b**, which in turn reacted with bromine in glacial acetic acid to yield 5-bromo derivatives **4a**, **b**. On the other hand, compounds **2a**, **b** were cyclocondensed with monochloroacetyl chloride, *p*-tolualdehyde in glacial acetic acid/pyridine, and ethyl bromoacetate to give the corresponding thiazolopyrimidines **5a**, **b**, **6a**, **b**, and **7a**, **b**, respectively; also compounds **2a**, **b** were hydrazinolyzed to compounds **8a**, **b**, which could be cyclized to triazolopyrimidines **9a**, **b** in presence of formic acid. They could also be condensed with *p*-anisaldehyde to give hydrazones **10a**, **b**. In another pathway, compounds **2a**, **b** were reacted with monochloroacetic acid in basic medium to give acetic acid derivatives **11a**, **b**. It can be deduced from the preliminary screening results that the cell lines most sensitive to the antiproliferative activity of tested compounds are human liver HEPG2 and colon cancer HT-29. All selected compounds exhibited moderate to strong growth inhibition activity against the HEPG2 cell line with 50 % inhibitory concentration (IC₅₀) ranging between 1 and 10 µg/ml. The most active compounds, which revealed antiproliferative activity also against human colon HT-29 and breast MCF-7 cell lines, were **3a**, **3b**, **4a**, and **10a**.

S. M. Awad · M. S. Mohamed
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan,
Egypt

O. A. Fathalla (✉) · A. M. Soliman
Therapeutic Chemistry Department, National Research Centre, Dokky, P.O. Box 12622, Cairo,
Egypt
e-mail: omarfathalla@yahoo.com

J. Wietrzyk · M. Milczarek
Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, 12,
Rudolf Weigl St., 53-114 Wrocław, Poland

Keywords New pyrimidine derivatives · 6-Sulfonamide derivatives · Thiazole · Triazole · Antiproliferative activity

Introduction

5-Fluorouracil (5-FU) is one of the oldest chemotherapy drugs [1] and has been in use for decades. It is an active medicine against many cancers including colon, rectal, pancreas, head, neck, and liver cancers [2]. It is also used topically as a cream or solution to treat basal cell cancer of skin and actinic keratoses, thus becoming the first prototype of pyrimidines in this field. Analogously, some 5-halogenated thiouracils have been synthesized and screened for anticancer activity. It has been reported that the tested compounds had comparable activity to that of uracils [3]. From 1957 to 2011, different research laboratories investigated the anticancer activity of some 5- and 6-substituted 2-thiouracils and reported that the tested compounds were found to inhibit DNA synthesis [4–11]. Based on these findings, the present work aims to synthesize a new group of pyrimidine compounds incorporated with different heterocycles to investigate whether the resulting compounds have better biological activity as antiproliferative agents against cancer, since all the selected pyrimidine derivatives were soluble in dimethyl sulfoxide (DMSO) at sufficient concentrations to allow cell experiments. The *in vitro* biological activity of these compounds was evaluated by their growth inhibitory potency against different cancer cell lines. The cytotoxic potency of compounds **3a**, **3b**, **4a**, **5b**, **6a**, **7b**, **8a**, **9b**, **10a**, and **11a** was studied in comparison with the known anticancer drugs 5-FU and cisplatin (CIS).

In continuation of our work on the synthesis of some 2-thiouracils [12], we report here the synthesis of novel thiouracil derivatives based on the diverse medicinal uses and biological activities of thiouracils as anticancer [12], antithyroid [13], and anti-infective agents [13–15]. In this work we screened some of the prepared compounds as anticancer agents in analogy to 5-FU, and we also develop a program to incorporate the thiouracil nucleus into thiazole and triazole nuclei to compare their activities with 5-FU as a reference standard, finally concluding that 5- and 6-substituted 2-thiouracils may have activity comparable to 5-FU.

Chemistry

All melting points are uncorrected and were determined in capillary tube on a Boetius melting-point microscope. Infrared (IR) spectra (KBr, cm^{-1}) were recorded from KBr discs. ^1H nuclear magnetic resonance (NMR) spectra were obtained on a Joel EX 270-MHz spectrometer with tetramethylsilane (TMS) as internal standard. Mass spectra were recorded on a SSQ 7000 mass spectrometer at 70 eV. All reactions were followed and checked by thin-layer chromatography (TLC) using chloroform/methanol (3:1), and spots were examined by ultraviolet (UV) lamp.

6-Amino-2-thiouracil (**1**)

This compound was prepared according to the reported method [16, 17].

N-(6-Oxo-2-thioxo-1,2,3,6-tetrahydropyrimidin-4-yl)benzenesulfonamide and 4-methyl-*N*-(6-oxo-2-thioxo-1,2,3,6-tetrahydropyrimidin-4-yl)benzenesulfonamide (**2a, b**)

A mixture of **1** (1.42 g of 0.05 mol), benzenesulfonyl chloride (0.88 g of 0.05 mol) or *p*-toluenesulfonyl chloride (0.95 g of 0.05 mol), and pyridine (0.4 ml) in methanol (25 ml) was refluxed for 12 h, then cooled; the reaction mixture was poured into ice/HCl, and the resulting solid formed was filtered off, washed with water, dried, and recrystallized from dimethylformamide (DMF)/water.

N-[2-(Methylsulfanyl)-6-oxo-1,6-dihydropyrimidin-4-yl]benzenesulfonamide and 4-methyl-*N*-[2-(methylsulfanyl)-6-oxo-1,6-dihydropyrimidin-4-yl]benzenesulfonamide (**3a, b**)

An amount (0.05 mol) of **2a, b** was dissolved in 25 ml 10 % alc. NaOH with stirring, then methyl iodide (0.05 mol) was added with stirring for 4 h, then the reaction mixture was neutralized with dil. HCl, filtered, dried, and recrystallized from methanol.

N-[5-Bromo-2-(methylsulfanyl)-6-oxo-1,6-dihydropyrimidin-4-yl]benzenesulfonamide and *N*-[5-bromo-2-(methylsulfanyl)-6-oxo-1,6-dihydropyrimidin-4-yl]-4-methylbenzenesulfonamide (**4a, b**)

An amount (0.05 mol) of **3a, b** was stirred with 0.05 mol bromine in 25 ml glacial acetic acid for 24 h, then the produced solid was filtered off, washed several times with water, dried, and recrystallized from methanol.

N-(2,5-Dioxo-2,3,8,8a-tetrahydro-5-*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-7-yl)benzenesulfonamide and *N*-(2,5-dioxo-2,3,8,8a-tetrahydro-5-*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-7-yl)-4-methylbenzenesulfonamide (**5a, b**)

To an ice-cold solution of **2a, b** (0.01 mol) in 40 ml dry DMF, triethylamine (0.01 mol) and chloroacetyl chloride (0.01 mol) were added successively. The reaction mixture was heated in a water bath at 70 °C for 6 h, cooled, poured into ice/cold water, and extracted with 3 × 30 ml methylene chloride; the organic layer was dried on anhydrous sodium sulfate and filtered off, and the filtrate was evaporated to dryness. The residue was washed with 10 % sodium carbonate solution, and the undissolved solid was filtered off, and crystallized from DMF/water.

N-[(2*E*)-2-(4-Methylbenzylidene)-3,5-dioxo-2,3,8,8a-tetrahydro-5*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-7-yl]benzenesulfonamide and 4-methyl-*N*-[(2*E*)-2-(4-methylbenzylidene)-3,5-dioxo-2,3,8,8a-tetrahydro-5*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-7-yl]benzenesulfonamide (**6a**, **b**)

A mixture of **2a**, **b** (0.001 mol) and *p*-tolualdehyde (0.001 mol) in 30 ml glacial acetic acid/acetic anhydride mixture was refluxed for 7 h, then cooled, and the produced solid was filtered off, dried, and crystallized from DMF/water.

N-(3,5-Dioxo-2,3,8,8a-tetrahydro-5*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-7-yl)benzenesulfonamide and *N*-(3,5-dioxo-2,3,8,8a-tetrahydro-5*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-7-yl)-4-methylbenzenesulfonamide (**7a**, **b**)

To an ice-cold solution of **2a**, **b** (0.01 mol) in 40 ml dry DMF, triethylamine (0.01 mol) and ethyl bromoacetate (0.01 mol) were added successively. The reaction mixture was heated in a water bath at 70 °C for 6 h, cooled, poured into ice/cold water, and extracted with methylene chloride (3 × 30 ml); the organic layer was dried on anhydrous sodium sulfate and filtered off, and the filtrate was evaporated to dryness. The residue was washed with 10 % sodium carbonate solution, and the undissolved solid was filtered off, and crystallized from DMF/water.

2a

Yield 75 %, m.p. 274 °C, Anal. Calcd. C₁₀H₉N₃O₃S₂ (283.33): C, 42.34; H, 3.20; N, 14.83. Found: C, 42.09; H, 3.45; N, 14.78; IR (KBr, cm⁻¹): 3,300 (NH), 3,100 (CH aromatic), 1,668 (C=O of thiouracil), 1,140, 1,320 (SO₂), 1,270 (C=S); ¹H NMR (DMSO-*d*₆) 6.8 (1H, s, thiouracil), 7.1–7.4 (5H, m), 9.8, 10.2, 10.5 (3NH, s, exchangeable with D₂O); MS: *m/z* 283.3 (M⁺, 27.1 %).

2b

Yield 57 %, m.p. 288 °C, Anal. Calcd. C₁₁H₁₁N₃O₃S₂ (297.36): C, 44.43; H, 3.73; N, 14.13. Found: C, 44.72; H, 3.95; N, 14.06; IR (KBr, cm⁻¹): 3,350 (NH), 3,100 (CH aromatic), 2,950 (CH, aliphatic), 1,676 (C=O of thiouracil), 1,143, 1,327 (SO₂), 1,276 (C=S); ¹H NMR (DMSO-*d*₆) 2.5 (H₃C-S), 6.7 (1H, s, thiouracil), 7.1–7.3 (4H, dd), 9.6, 10.4, 10.7 (3NH, s, exchangeable with D₂O); MS: *m/z* 297.4 (M⁺, 39.3 %).

3a

Yield 63 %, m.p. 301 °C, Anal. Calcd. C₁₁H₁₂N₃O₃S₂ (297.36): C, 44.43; H, 3.73; N, 14.13. Found: C, 44.09; H, 4.38; N, 13.99; IR (KBr, cm⁻¹): 3,387 (NH), 2,978 (CH aliphatic), 3,167 (CH aromatic), 1,665 (C=O of thiouracil), 1,143, 1,325 (SO₂), 1,274 (C=S); ¹H NMR (DMSO-*d*₆) 2.3 (H₃C-S), 6.9 (1H, s, thiouracil), 7.1–7.3 (5H, m), 9.9, 10.5 (2NH, s, exchangeable with D₂O); MS: *m/z* 297.4 (M⁺, 15.8 %).

3b

Yield 78 %, m.p. 361 °C, Anal. Calcd. C₁₂H₁₄N₃O₃S₂ (312.38): C, 46.13; H, 4.52; N, 13.45, Found: C, 46.44; H, 4.66; N, 13.19; IR (KBr, cm⁻¹): 3,348 (NH), 2,990 (CH aliphatic), 3,177 (CH aromatic), 1,685 (C=O of thiouracil), 1,148, 1,337 (SO₂), 1,271 (C=S); ¹H NMR (DMSO-*d*₆), 2.3, 2.5 (2 H₃C-S), 6.8 (1H, s, thiouracil), 7.2–7.4 (4H, dd), 9.8, 10.8 (2NH, s, exchangeable with D₂O); MS: *m/z* 312.4 (M⁺, 33.05 %).

4a

Yield 80 %, m.p. 276 °C, Anal. Calcd. C₁₁H₁₀N₃O₃S₂ Br (376.27): C, 35.11; H, 2.68; N, 11.17. Found: C, 35.07 H, 2.57; N, 11.38; IR (KBr, cm⁻¹): 3,355 (NH), 2,968 (CH aliphatic), 3,168 (CH aromatic), 1,678 (C=O of thiouracil), 1,139, 1,320 (SO₂), 1,274 (C=S); ¹H NMR (DMSO-*d*₆), 2.4 (H₃C-S), 7.1–7.3 (5H, m), 9.9, 10.4 (2NH, s, exchangeable with D₂O); MS: *m/z* 376.3 (M⁺, 18.1 %), 378.2 (M+2)⁺ (17.4 %).

4b

Yield 69 %, m.p. 298 °C, Anal. Calcd. C₁₂H₁₂N₃O₃S₂ Br (390.28): C, 36.92; H, 3.10; N, 10.77. Found: C, 37.01; H, 3.21; N, 10.82; IR (KBr, cm⁻¹): 3,350 (NH), 2,968 (CH aliphatic), 3,139 (CH aromatic), 1,685 (C=O of thiouracil), 1,142, 1,328 (SO₂); ¹H NMR (DMSO-*d*₆), 2.3, 2.4 (2 H₃C-S), 7.2, 7.3 (4H, dd), 9.8, 10.2 (2NH, s, exchangeable with D₂O); MS: *m/z* 390.3 (M⁺, 26.2 %), 392.7 (M+2)⁺ (25.7 %).

5a

Yield 70 %, m.p. 253 °C, Anal. Calcd. C₁₂H₉N₃O₄S₂ (323.34): C, 44.57; H, 2.81; N, 12.99. Found: C, 44.38; H, 2.97; N, 13.07; IR (KBr, cm⁻¹): 3,300 (NH), 3,154 (CH aromatic), 1,668 (C=O of pyrimidine), 1,723 (C=O of thiazole), 1,140, 1,320 (SO₂); ¹H NMR (DMSO-*d*₆), 2.2 (2H of thiazole) 6.8 (1H, s, pyrimidine), 7.1–7.4 (5H, m), 9.8 (1H, s, exchangeable with D₂O); MS: *m/z* 323.3 (M⁺, 16.1 %).

5b

Yield 68 %, m.p. 280 °C, Anal. Calcd. C₁₃H₁₁N₃O₄S₂ (337.38): C, 46.28; H, 3.29; N, 12.45. Found: C, 46.19; H, 3.40; N, 12.62; IR (KBr, cm⁻¹): 3,320 (NH), 3,164 (CH aromatic), 1,688 (C=O of pyrimidine), 1,721 (C=O of thiazole), 1,140, 1,320 (SO₂); ¹H NMR (DMSO-*d*₆), 2.2 (2H of thiazole), 2.5 (3H, s), 6.8 (1H, s, pyrimidine), 7.1–7.3 (4H, dd), 9.7 (1H, s, exchangeable with D₂O); MS: *m/z* 337.4 (M⁺, 12.56 %).

6a

Yield 59 %, m.p. 308 °C, Anal. Calcd. C₂₀H₁₅N₃O₄S₂ (425.48): C, 56.45; H, 3.55; N, 9.88. Found: C, 56.67; H, 3.47; N, 9.97; IR (KBr, cm⁻¹): 3,354 (NH), 3,109 (CH

aromatic), 1,680 (C=O of pyrimidine), 1,728 (C=O of thiazole), 1,140, 1,320 (SO₂); ¹H NMR (DMSO-d₆), 2.1 (3H, s, CH₃), 6.2 (1H, s, C=CH), 6.7 (1H, s, pyrimidine), 7.1–7.7 (9H, m), 9.5 (1H, s, exchangeable with D₂O); MS: *m/z* (%) 425.5 (M)⁺ (70.53 %).

6b

Yield 73 %, m.p. 319 °C, Anal. Calcd. C₂₁H₁₇N₃O₄S₂ (439.51): C, 57.34; H, 3.89; N, 9.56. Found: C, 57.44; H, 3.87; N, 9.48; IR (KBr, cm⁻¹): 3,377 (NH), 3,137 (CH aromatic), 1,685 (C=O of pyrimidine), 1,730 (C=O of thiazole), 1,140, 1,320 (SO₂); ¹H NMR (DMSO-d₆), 2.1, 2.2 (6H, s, 2 CH₃), 6.2 (1H, s, C=CH), 6.9 (1H, s, pyrimidine), 7.4–7.7 (8H, m), 9.4 (1H, s, exchangeable with D₂O); MS: *m/z* 439.5 (M⁺, 48.09 %).

7a

Yield 77 %, m.p. 325 °C, Anal. Calcd. C₁₂H₉N₃O₄S₂ (323.34): C, 44.57; H, 2.81; N, 12.99. Found: C, 44.56; H, 2.67; N, 13.20; IR (KBr, cm⁻¹): 3,320 (NH), 3,174 (CH aromatic), 1,670 (C=O of pyrimidine), 1,727 (C=O of thiazole), 1,145, 1,323 (SO₂); ¹H NMR (DMSO-d₆) 2.4 (2H of thiazole), 6.9 (1H, s, pyrimidine), 7.1–7.3 (5H, m), 9.8 (1H, s, exchangeable with D₂O); MS: *m/z* (%) 323.3 (M)⁺ (10.76 %).

7b


Yield 65 %, m.p. 372 °C, Anal. Calcd. C₁₃H₁₁N₃O₄S₂ (337.38): C, 46.28; H, 3.29; N, 12.45. Found: C, 46.37; H, 3.40; N, 12.58; IR (KBr, cm⁻¹): 3,300 (NH), 3,157 (CH aromatic), 1,685 (C=O of pyrimidine), 1,722 (C=O of thiazole), 1,140, 1,320 (SO₂); ¹H NMR (DMSO-d₆), 2.3 (2H of thiazole), 2.5 (3H, s, CH₃), 6.8 (1H, s, pyrimidine), 7.1–7.4 (4H, dd), 9.7 (1H, s, exchangeable with D₂O); MS: *m/z* 337.4 (M⁺, 33.09 %) (Scheme 1).

N-(2-Hydrazinyl-6-oxo-1,6-dihydropyrimidin-4-yl)benzenesulfonamide and *N*-(2-hydrazinyl-6-oxo-1,6-dihydropyrimidin-4-yl)-4-methylbenzenesulfonamide (**8a**, **b**)

A mixture of **2a**, **b** (0.005 mol) and hydrazine hydrate 99 % (0.005 mol) in 30 ml methanol was refluxed for 30 h, then cooled and poured into ice/water; the produced solid was filtered off, dried, and crystallized from methanol.

N-(5-Oxo-1,5-dihydro[1,2,4]triazolo[4,3-*a*]pyrimidin-7-yl)benzenesulfonamide and 4-methyl-*N*-(5-oxo-1,5-dihydro[1,2,4]triazolo[4,3-*a*]pyrimidin-7-yl)benzenesulfonamide (**9a**, **b**)

A mixture of **8a**, **b** (0.001 mol) and 30 ml formic acid was refluxed for 8 h, then cooled and poured into ice/water; the precipitate was filtered off, dried, and crystallized from methanol.



Scheme 1 The structure of compounds: **3a,b-7a,b**

N-{2-[(2*E*)-2-(4-Methoxybenzylidene)hydrazinyl]-6-oxo-1,6-dihydropyrimidin-4-yl}-4-methylbenzenesulfonamide and *N*-{2-[(2*E*)-2-(4-methoxybenzylidene)hydrazinyl]-6-oxo-1,6-dihydropyrimidin-4-yl}benzenesulfonamide (**10a, b**)

A mixture of **8a, b** (0.001 mol) and *p*-anisaldehyde (0.001 mol) in 30 ml methanol was refluxed for 8 h, then cooled, and the produced precipitate was filtered off, dried, and crystallized from DMF/water.

[(4-{[Phenylsulfonyl]amino}-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]acetic acid and [(4-{[(4-methylphenyl)sulfonyl]amino}-6-oxo-1,6-dihydropyrimidin-2-yl)sulfanyl]acetic acid (**11a, b**)

To a solution of monochloroacetic acid (0.03 mol) and sodium hydroxide (0.03 mol) in 5 ml water, a solution of **2a, b** (0.03 mol) and sodium hydroxide (0.03 mol) was added. The reaction mixture was stirred at ambient temperature for 3 h, then rendered acidic with hydrochloric acid (6 N). The separated solid was filtered off, washed with water, dried, and crystallized from methanol.

8a

Yield 61 %, m.p. 277 °C, Anal. Calcd. $\text{C}_{10}\text{H}_{11}\text{N}_5\text{O}_3\text{S}$ (281.13): C, 42.72; H, 3.94; N, 24.91. Found: C, 42.75 H, 3.70; N, 24.83; IR (KBr, cm^{-1}): 3,301 (NH), 3,167 (CH aromatic), 1,665 (C=O of pyrimidine), 1,143, 1,325 (SO_2); ^1H NMR (DMSO- d_6), 3.1, 6.2, 6.8, 10.5 (NH_2 , 3NH, s, exchangeable with D_2O), 6.9 (1H, s, pyrimidine), 7.1–7.3 (5H, m); MS: m/z 281.1 (M^+ , 18.95 %).

8b

Yield 70 %, m.p. 253 °C, Anal. Calcd. C₁₁H₁₃N₅O₃S (295.32): C, 44.73; H, 4.44; N, 23.72. Found: C, 44.58; H, 4.37; N, 23.86; IR (KBr, cm⁻¹): 3,312 (NH), 3,176 (CH aromatic), 1,676 (C=O of pyrimidine), 1,143, 1,325 (SO₂); ¹H NMR (DMSO-*d*₆), 3.2, 6.4, 6.8, 10.3 (NH₂, 3NH, s, exchangeable with D₂O), 2.4 (3H, s, CH₃), 6.7 (1H, s, pyrimidine), 7.1–7.4 (4H, dd); MS: *m/z* 295.3 (M⁺, 54.94 %).

9a

Yield 66 %, m.p. 267 °C, Anal. Calcd. C₁₁H₉N₅O₃S (291.30): C, 45.35; H, 3.11; N, 24.05. Found: C, 45.07; H, 3.45; N, 23.97; IR (KBr, cm⁻¹): 3,354 (NH), 2,978, 3,168 (CH aromatic), 1,675 (C=O of pyrimidine), 1,140, 1,327 (SO₂); ¹H NMR (DMSO-*d*₆), 6.9 (1H, s, thiouracil), 7.1 (1H, s, triazole), 7.2–7.4 (5H, m), 8.1, 9.5 (2NH, s, exchangeable D₂O); MS: *m/z* 291.3 (M⁺, 25.98 %).

9b

Yield 59 %, m.p. 295 °C, Anal. Calcd. C₁₂H₁₁N₅O₃S (305.32): C, 47.19; H, 3.63; N, 22.94. Found: C, 47.32; H, 3.57; N, 22.97; IR (KBr, cm⁻¹): 3,300 (NH), 3,168 (CH aromatic), 1,679 (C=O of pyrimidine), 1,140, 1,327 (SO₂); ¹H NMR (DMSO-*d*₆), 2.5 (3H, s, CH₃), 6.9 (1H, s, pyrimidine), 7.0 (1H, s, triazole), 7.1–7.3 (4H, dd), 8.2, 9.4 (2NH, s, exchangeable with D₂O); MS: *m/z* 305.3 (M⁺, 9.85 %).

10a

Yield 74 %, m.p. 321 °C, Anal. Calcd. C₁₈H₁₇N₅O₄S (399.43): C, 54.12; H, 4.29; N, 17.53. Found: C, 54.07; H, 4.35; N, 17.25; IR (KBr, cm⁻¹): 3,391 (NH), 3,197 (CH aromatic), 1,675 (C=O of pyrimidine), 1,145, 1,328 (SO₂); ¹H NMR (DMSO-*d*₆), 4.1 (3H, s, OCH₃), 6.1 (1H, s, CH=N-), 6.2, 6.8, 10.5 (3NH, s, exchangeable with D₂O), 6.9 (1H, s, pyrimidine), 7.1–7.4 (9H, m); MS: *m/z* 399.4 (M⁺, 7.93 %).

10b

Yield 67 %, m.p. 347 °C, Anal. Calcd. C₁₉H₁₉N₅O₄S (413.45): C, 55.19; H, 4.63; N, 16.94. Found: C, 55.50; H, 4.57; N, 16.76; IR (KBr, cm⁻¹): 3,388 (NH), 3,165 (CH aromatic), 1,687 (C=O of pyrimidine), 1,140, 1,326 (SO₂); ¹H NMR (DMSO-*d*₆), 2.5 (3H, s, CH₃), 4.2 (3H, s, OCH₃), 6.2 (1H, s, CH=N-), 6.1, 6.8, 10.4 (3NH, s, exchangeable with D₂O), 6.9 (1H, s, pyrimidine), 7.1–7.3 (8H, m); MS: *m/z* 413.5 (M⁺, 12.07 %).

11a

Yield 68 %, m.p. 335 °C, Anal. Calcd. C₁₂H₁₁N₃O₅S₂ (341.36): C, 42.22; H, 3.25; N, 12.31. Found: C, 42.58; H, 2.98; N, 12.45; IR (KBr, cm⁻¹): 3,405 (OH) very broad due to hydrogen bonding, 3,300 (NH), 2,958 (CH- aliphatic), 3,167 (CH

aromatic), 1,675 (C=O of thiouracil), 1,750 (CO of COOH), 1,143, 1,325 (SO₂); ¹H NMR (DMSO-*d*₆), 3.3 (2H, s, CH₂), 6.9 (1H, s, pyrimidine), 7.1–7.4 (5H, m), 9.9, 10.5 (2NH, s, exchangeable with D₂O), 11.7 (1H, s, COOH); MS: *m/z* 341.4 (M⁺, 19.87 %).

11b


Yield 60 %, m.p. 359 °C, Anal. Calcd. C₁₃H₁₃N₃O₅S₂ (355.39): C, 43.93; H, 3.69; N, 11.82. Found: C, 43.69; H, 3.78; N, 11.78; IR (KBr, cm⁻¹): 3,400 (OH) very broad due to hydrogen bonding, 3,300 (NH), 2,960 (CH– aliphatic), 3,100 (CH aromatic), 1,670 (C=O of thiouracil), 1,754 (C=O of COOH), 1,140, 1,322 (SO₂); ¹H NMR (DMSO-*d*₆), 2.5 (3H, s, CH₃), 3.4 (2H, s, CH₂), 6.7 (1H, s, pyrimidine), 7.2–7.4 (4H, dd), 9.8, 10.3 (2NH, s, exchangeable with D₂O), 11.8 (1H, s, COOH); MS: *m/z* 355.4 (M⁺, 23.84 %) (Scheme 2).

Biological investigation

On the basis of monitoring the inhibition of the growth of human cancer cells, a series of novel pyrimidine derivatives possessing a broader spectrum of antitumor activity and fewer toxic side-effects than traditional anticancer drugs have been studied.

Ten selected pyrimidine derivatives (**3a**, **3b**, **4a**, **5b**, **6a**, **7b**, **8a**, **9b**, **10a**, and **11a**) were subjected to screening for investigation of their antiproliferative potency against human A549 (lung), MCF-7 (breast), HT-29 (colon), and HEPG2 (liver) cancer cell lines.

The results indicate that the cell lines most sensitive to the antiproliferative activity of tested compounds are human liver HEPG2 and colon HT-29. In the case of human liver HEPG2, compounds **4a**, **3a**, **5a**, and **10a** showed the highest



Scheme 2 The structure of compounds: **8a,b**–**11a,b**

antiproliferative activity compared with other compounds. On the other hand, in the case of colon cancer HT-29, only compound **4a** showed moderate activity in comparison with other compounds.

In this study, we have identified some pyrimidine derivatives as a novel class of compounds with antiproliferative activity. The lead compounds were the most potent in the biological assay employed (showing, e.g., improved growth inhibition potential as compared with the reference anticancer drugs).

These experimental findings may provide support for use of these novel compounds as new weapons in the fight against different types of cancer.

Materials and methods

Cells

Cell lines

Two groups of cell lines were used in this work: (1) The first group: A549 (human lung cancer), MCF-7 (human breast cancer), and HT-29 (human colon cancer) are maintained in the Institute of Immunology and Experimental Therapy, Wrocław, Poland. Cell lines A549 and HT-29 were cultured in medium Opti-MEM (Gibco, Scotland, USA) and RPMI 1640 (IET, Wrocław, Poland) supplemented with 2 mM L-glutamine, fetal bovine serum (5 %) (all from Sigma-Aldrich Chemie GmbH, Steinheim, Germany), 100 U/ml penicillin and 100 µg/ml streptomycin (both from Polfa Tarchomin S.A., Warsaw, Poland), and 1 mM sodium pyruvate (from Sigma-Aldrich Chemie GmbH, Steinheim, Germany), only in case of HT-29 cell line. Cell line MCF-7 was cultured in Eagle medium (IET, Wrocław, Poland) supplemented with 2 mM L-glutamine, 0.01 mg/ml insulin, 1 mM sodium pyruvate, fetal bovine serum (10 %) (all from Sigma-Aldrich Chemie GmbH, Steinheim, Germany), and 100 U/ml penicillin and 100 µg/ml streptomycin (both from Polfa Tarchomin S.A., Warsaw, Poland). All lines were obtained from the American Type Culture Collection (Rockville, MD, USA). Cells were cultured at 37 °C in humid atmosphere saturated with 5 % CO₂. (2) The second group: HEPG2 (human liver cancer cell line), is maintained at the National Institute of Cancer, Cairo University, Cairo, Egypt.

Compounds

Prior to usage, the newly synthesized compounds (**3a**, **3b**, **4a**, **5b**, **6a**, **7b**, **8a**, **9b**, **10a**, and **11a**) were dissolved in DMSO and culture medium (1:9) to concentration of 1 mg/ml and subsequently diluted in culture medium to reach the required concentrations (ranging from 1 to 100 µg/ml).

Antiproliferative assay in vitro

At 24 h before addition of the tested compounds, the cells were placed in 96-well plates (Sarstedt, Germany) at density of 1×10^4 cells per well. An assay was

performed after 72 h of exposure to varying concentrations of the tested agents. The *in vitro* cytotoxic effect of all agents was examined using the sulforhodamine B (SRB) assay [18].

SRB cytotoxicity test

Cells were attached to the bottom of plastic wells by fixing them with cold 50 % trichloroacetic acid (TCA; Sigma-Aldrich Chemie GmbH, Steinheim, Germany) on the top of the culture medium in each well. The plates were incubated at 4 °C for 1 h, then washed five times with tap water. The cellular material fixed with TCA was stained with 0.04 % sulforhodamine B (SRB; Sigma-Aldrich Chemie GmbH, Steinheim, Germany) dissolved in 1 % acetic acid (POCH, Gliwice, Poland) for 30 min. Unbound dye was removed by rinsing (4×) in 1 % acetic acid. The protein-bound dye was extracted with 10 mM unbuffered Tris base (POCH, Gliwice, Poland) for determination of the optical density ($\lambda = 540$ nm) in a computer-interfaced, 96-well microtiter plate reader (Multiskan RC photometer; Labsystems, Helsinki, Finland).

The results were calculated as an IC₅₀ (50 % inhibitory concentration) value, i.e., the concentration of tested agent which inhibits proliferation of 50 % of the cancer cell population. IC values were calculated for each experiment separately, and mean values with standard deviation (SD) are presented in the table. Each compound at each concentration was tested in triplicate in a single experiment, which was repeated 3–7 times.

Results

Table 1 indicates the cytotoxic activity of the newly synthesized derivatives **3a**, **3b**, **4a**, **5b**, **6a**, **7b**, **8a**, **9b**, **10a**, and **11a** against various cancer cell lines. Their activity was compared with the traditional anticancer drugs 5-FU and CIS. It can be deduced from the preliminary screening results that the cell lines most sensitive to the antiproliferative activity of tested compounds are human liver HEPG2 and colon cancer HT-29. All selected compounds exhibited moderate to strong growth inhibition activity against HEPG2 cell line with IC₅₀ values ranging between 1 and 10 µg/ml. The most active compounds, which revealed antiproliferative activity also against human colon HT-29 and breast MCF-7 cell lines, were **3a**, **3b**, **4a**, and **10a**.

Discussion

Cytotoxic drugs remain the mainstay of cancer chemotherapy, being administered in novel therapeutic approaches such as signal inhibition. It is therefore important to discover novel cytotoxic agents with spectra of activity and toxicity that differ from currently used agents. It is well known that chemotherapy aims to destroy cancer cells using various types of chemicals. The substances used are supposed to target

Table 1 Antiproliferative activity of some selected newly synthesized compounds against different carcinoma cell lines

Compound	IC ₅₀ (µg/ml)			
	A549	MCF-7	HT-29	HEPG2
3a	na	51.69 ± 8.0	6.93 ± 1.65	4.1
3b	55.39 ± 6.53	40.51 ± 8.26	14.72 ± 3.56	3.92
4a	na	67.86 ± 11.04	46.99 ± 9.21	4.31
5a	na	na	na	9.38
6a	na	na	na	6.59
7b	na	na	na	6.53
8a	na	54.41 ± 8.70	na	8.54
9b	na	na	na	8.48
10a	41.77 ± 9.13	25.74 ± 4.47	14.35 ± 3.54	3.74
11a	na	na	na	7.43
Cisplatin	4.08 ± 0.43	3.34 ± 0.52	4.30 ± 3.67	3.58
5-Fluorouracil	7.22 ± 0.44	3.65 ± 0.93	0.37 ± 0.28	5
DMSO	na*	na*	na*	na*

na not active at tested concentration (from 100 to 0.1 µg/ml), na* not active at the highest concentration of DMSO (1 % solution)

mainly cancer cells, and doses are calculated to minimize collateral damage to surrounding tissues, which nevertheless occurs. This type of treatment increases the entropy of the organism, suppresses the immune system, and forms a toxic cell environment which may destroy surrounding healthy cells. So, it is important to minimize effective doses to the least amount, as well as to try to minimize the side-effects of these drugs. Therefore, novel pyrimidine derivatives with a comparable spectrum of antiproliferative activity to 5-FU, but potentially fewer side-effects, were developed. The antiproliferative activities of such compounds were assessed against the HEPG2 cancer cell line in comparison with the traditional anticancer drugs 5-FU and CIS. In the antiproliferative activity study, some of the selected compounds showed reasonable antiproliferative activity in comparison with 5-FU and CIS. Moreover, study of the biochemical parameters induced in mice by the tested compounds showed insignificant differences relative to the control group, which indicates a moderate margin of safety for the selected compounds. Compared with 5-FU and doxorubicin (DOX), dose augmentation of compounds **10a** and **11a**, in a search for possibly higher potency, therefore seems realizable without undesirable implications. Furthermore, the selected compounds have important potential advantages over 5-FU and DOX because of their lower toxicity and their ability to induce lower biochemical parameters. These results are in agreement with the work of many authors who have reported novel derivatives of 5-FU with a broader spectrum of antitumor activity and fewer toxic side-effects than 5-FU.

Conclusions

Various compounds were selected for further structural modification in an effort to increase their potency. The goal of the present work is to explore the significance of the spacer for the respective biological anticancer activity. The anticancer activity data indicate that the cell lines most sensitive to the activity of tested compounds are human liver HEPG2 and colon cancer HT-29. In the case of human liver HEPG2, compounds **3a**, **3b**, **4a**, and **10a** showed the highest antiproliferative activity compared with other compounds. On the other hand, in the case of colon cancer HT-29, only compound **3a** showed moderate activity in comparison with other compounds.

Acknowledgments The authors are grateful and offer their deep thanks to the members of the Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Division, National Research Centre, and the Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, 12, Rudolf Weigl St. 53-114, Wrocław, Poland for helping them to do this work.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. C.A. Heidelberger, K.C. Leibman, P.M. Bhargava, *Cancer Res.* **17**, 39 (1957)
2. B.H. Longley, D.P. Harkin, P.G. Tohnston, *Nat. Rev. Cancer* **3**(5), 330–338 (2003)
3. M.J. Straus, N.B. Mantel, A.H. Goldin, *Cancer Res.* **35**, 126 (1962)
4. E.N. Sassenrath, A.M. Kells, D.M. Greenberg, *Cancer Res.* **19**, 259 (1959)
5. M.A. Friedland, D.W. Visser, *Biochem. Biophys. Acta* **51**, 148 (1961)
6. G.M. Vansanten, F.A. Sorm, E.H. Siman, *J. Biol. Chem.* **237**, 1271 (1965)
7. R.K. Zahn, U.K. Hagen, *Mol. Pharmac.* **1**, 113 (1972)
8. C.G. Tomisek, P.W. Todd, E.F. Borex, *Canadian Cancer Res. Conference* (Pergamon press, 1995), p. 34
9. T. Pospieszny, M. Szymankiewicz, E. Wyrzykiewicz, *ISRN Org. Chem.* **2011**, 6 (2011). Article ID 610521
10. S. Mosaad, S. Mohamed, M. Awad, S.I. Amira Ibrahim, *Molecules* **15**, 1882–1890 (2010)
11. T.S. Chitre, K.G. Bothara, S.M. Patil, K.D. Asgaonkar, S. Nagappa, M.K. Kathiravan, *Int. J. Res. Pharm. Biomed. Sci.* **2**(2), 616–623 (2011)
12. O.A. Fathalla, W.A. Zaghary, H.H. Radwan, S.M. Awad, M.S. Mohamed, *Arch. Pharm. Res.* **25**(3), 258–269 (2002)
13. M. Nakamura, S. Jonsson, *Arch. Biochem. Biophys.* **66**, 183–189 (1957)
14. V.J. Ram, *Archiv der Pharmazie.* **324**(11), 837–839 (1991)
15. V.J. Ram, A.S. Goel, M.K. Nath, P.H. Srivastava, *Prog. Drug Res.* **52**, 53–101 (1999)
16. C. Taylor, J. Edward, C. Cheng, *J. Org. Chem.* **25**, 148 (1960)
17. S. Youssif, S. El-Bahaie, E. Nabih, *Bull. Korean Chem. Soc.* **24**(10), 1429–1432 (2003)
18. C. Wiart, *Evid. Based Complement Alternat. Med.* **4**(3), 299–311 (2007)